Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial - PubMed (original) (raw)
Randomized Controlled Trial
. 2017 Oct;177(4):1024-1032.
doi: 10.1111/bjd.15707. Epub 2017 Sep 12.
Affiliations
- PMID: 28580646
- DOI: 10.1111/bjd.15707
Randomized Controlled Trial
Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial
M Sticherling et al. Br J Dermatol. 2017 Oct.
Erratum in
- Corrigendum.
[No authors listed] [No authors listed] Br J Dermatol. 2017 Dec;177(6):1772. doi: 10.1111/bjd.16086. Br J Dermatol. 2017. PMID: 29313919 No abstract available.
Abstract
Background: Secukinumab is a fully human antibody that neutralizes interleukin-17A. It has significant efficacy and a favourable safety profile in moderate-to-severe plaque psoriasis and psoriatic arthritis.
Objectives: To compare secukinumab with fumaric acid esters (FAEs) in a randomized controlled trial.
Methods: In this 24-week, randomized, open-label, multicentre study with blinded assessment, patients with moderate-to-severe plaque psoriasis, naive to systemic treatments, were randomized to receive secukinumab 300 mg subcutaneously or oral FAEs. The primary end point was ≥ 75% improvement from baseline Psoriasis Area and Severity Index score (PASI 75 response) at week 24, and missing patients were considered responders if they were responders at the time of dropout.
Results: In total 202 patients were randomized and 200 were treated with at least one dose. Outcomes at week 24 were available for 147 and imputed for 53 patients. Discontinuations were mostly due to adverse events, and occurred more frequently in the FAE group (1·9% vs. 40·0%). At week 24, significantly more patients receiving secukinumab compared with FAEs achieved PASI 75 response (89·5% vs. 33·7%, P < 0·001), PASI 90 response (75·2% vs. 18·9%, P < 0·001) and Dermatology Life Quality Index 0 or 1 response (71·4% vs. 25·3%, P < 0·001).
Conclusions: Secukinumab demonstrated superior efficacy to FAEs in patients with psoriasis over a 24-week period.
© 2017 British Association of Dermatologists.
Comment in
- First-line systemic treatment of psoriasis: staying conventional or going biologic?
Balak DMW. Balak DMW. Br J Dermatol. 2017 Oct;177(4):897-898. doi: 10.1111/bjd.15885. Br J Dermatol. 2017. PMID: 29052873 No abstract available.
Similar articles
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Thaçi D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, Ziv M, Pinter A, Hugot S, You R, Milutinovic M. Thaçi D, et al. J Am Acad Dermatol. 2015 Sep;73(3):400-9. doi: 10.1016/j.jaad.2015.05.013. Epub 2015 Jun 17. J Am Acad Dermatol. 2015. PMID: 26092291 Clinical Trial. - Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, Haemmerle S, Thurston HJ, Papavassilis C, Richards HB. Papp KA, et al. Br J Dermatol. 2013 Feb;168(2):412-21. doi: 10.1111/bjd.12110. Epub 2013 Jan 18. Br J Dermatol. 2013. PMID: 23106107 Clinical Trial. - Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS).
Thaçi D, Pinter A, Sebastian M, Termeer C, Sticherling M, Gerdes S, Wegner S, Krampe S, Bartz H, Rausch C, Mensch A, Eyerich K. Thaçi D, et al. Br J Dermatol. 2020 Aug;183(2):265-275. doi: 10.1111/bjd.18696. Epub 2020 Jan 20. Br J Dermatol. 2020. PMID: 31705526 Clinical Trial. - Secukinumab (AIN457) for the treatment of psoriasis.
López-Ferrer A, Vilarrasa E, Puig L. López-Ferrer A, et al. Expert Rev Clin Immunol. 2015;11(11):1177-88. doi: 10.1586/1744666X.2015.1095092. Epub 2015 Oct 1. Expert Rev Clin Immunol. 2015. PMID: 26428036 Review. - Fumaric acid esters for psoriasis: a systematic review.
Smith D. Smith D. Ir J Med Sci. 2017 Feb;186(1):161-177. doi: 10.1007/s11845-016-1470-2. Epub 2016 Jun 7. Ir J Med Sci. 2017. PMID: 27271164 Review.
Cited by
- Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Guelimi R, Garcia-Doval I, Hua C, Hughes C, Naldi L, Kinberger M, Afach S, Le Cleach L. Sbidian E, et al. Cochrane Database Syst Rev. 2023 Jul 12;7(7):CD011535. doi: 10.1002/14651858.CD011535.pub6. Cochrane Database Syst Rev. 2023. PMID: 37436070 Free PMC article. Review. - Adverse events associated with anti-IL-17 agents for psoriasis and psoriatic arthritis: a systematic scoping review.
Wang J, Wang C, Liu L, Hong S, Ru Y, Sun X, Chen J, Zhang M, Lin N, Li B, Li X. Wang J, et al. Front Immunol. 2023 Jan 31;14:993057. doi: 10.3389/fimmu.2023.993057. eCollection 2023. Front Immunol. 2023. PMID: 36817423 Free PMC article. - Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Garcia-Doval I, Doney L, Dressler C, Hua C, Hughes C, Naldi L, Afach S, Le Cleach L. Sbidian E, et al. Cochrane Database Syst Rev. 2022 May 23;5(5):CD011535. doi: 10.1002/14651858.CD011535.pub5. Cochrane Database Syst Rev. 2022. PMID: 35603936 Free PMC article. Updated. Review. - Long-Term Treatment with Dimethyl Fumarate for Plaque Psoriasis in Routine Practice: Good Overall Effectiveness and Positive Effect on Impactful Areas.
Augustin M, Landeck L, Diemert S, Asadullah K, Hammann U, Ertner K, Hadshiew I. Augustin M, et al. Dermatol Ther (Heidelb). 2022 May;12(5):1121-1131. doi: 10.1007/s13555-022-00714-0. Epub 2022 Apr 11. Dermatol Ther (Heidelb). 2022. PMID: 35403945 Free PMC article. - Common Fundamentals of Psoriasis and Depression.
Hölsken S, Krefting F, Schedlowski M, Sondermann W. Hölsken S, et al. Acta Derm Venereol. 2021 Nov 30;101(11):adv00609. doi: 10.2340/actadv.v101.565. Acta Derm Venereol. 2021. PMID: 34806760 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical